Study finds increased risk of stroke following shingles, suggests antiviral treatment may
Patients' risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study in Clinical Infectious Diseases, now available online.
People with shingles, an often painful skin rash caused by the same virus that causes chickenpox, had a higher stroke risk in the first 6 months after shingles symptoms appeared; this risk was particularly increased in patients with a rash near their eyes, the study found.
Shingles, or herpes zoster, is a significant public health problem, affecting an estimated 1 million adults in the U.S. and nearly 90,000 in the U.K. each year. The disease develops when the varicella-zoster virus, which causes chickenpox in children and then remains dormant in the body, reactivates later in life.
Sinéad Langan, MD, PhD, and colleagues at the London School of Hygiene & Tropical Medicine identified patients with first-ever incidents of shingles and stroke, and also examined antiviral treatment records for shingles, drawing from a database of information from patients across 600 general practices in the U.K.
Researchers compared the risk of stroke in the time period after the patient had shingles to time periods when the patient did not have recent shingles. Among the 6,584 patients included in the study, the stroke rate was 63 percent higher in the first four weeks after a shingles episode compared to the patient's baseline risk, diminishing slowly up to 6 months later. The stroke risk increased up to three-fold for a short period of time among those with a shingles rash affecting the skin around their eyes, compared to baseline risk.
In patients treated with oral antiviral medication for their shingles—55 percent of study participants—the risk of stroke was lower than in those not treated with antivirals. "The relatively low prescribing rates of antiviral therapy in U.K. general practice after developing shingles need to be improved," Dr. Langan said, "as our study suggests that stroke risks following shingles are lower in those treated with oral antiviral therapy compared to individuals not treated with antiviral therapy."
The findings also highlight the importance of vaccinating older adults against shingles, which can reduce the risk of developing the painful condition in the first place. A shingles vaccine is available and recommended for adults over 60 in the U.S. and for those in their 70s in the U.K.
In a related editorial, Maria A. Nagel, MD, and Donald H. Gilden, MD, of the University of Colorado School of Medicine, noted that the findings confirm previous studies of shingles and stroke risk from Taiwan, Denmark, and the U.K. This latest study is "the first to show that the increased risk of stroke after zoster can be reduced with antiviral treatment," they wrote.
Editor's note: The research was funded by the U.K.'s National Institute for Health Research (NIHR) and the Stroke Association. The views expressed are those of the author(s) and not necessarily those of the funders, the U.K. National Health Service (NHS), or the U.K. Department of Health.
1. An often painful skin rash, shingles (herpes zoster) affects an estimated 1 million adults in the U.S. and nearly 90,000 in the U.K. each year.
2. People with shingles, particularly those with a rash near their eyes, had a higher stroke risk in the first 6 months after their symptoms appeared, this study found.
3. Antiviral treatment for shingles appeared to lower this increased risk of stroke.
Clinical Infectious Diseases is a leading journal in the field of infectious disease with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.
Matt Sobczak | idw - Informationsdienst Wissenschaft
Researchers simplify tiny structures' construction drip by drip
12.11.2018 | Princeton University, Engineering School
Mandibular movement monitoring may help improve oral sleep apnea devices
06.11.2018 | Elsevier
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences